GS•benzinga•
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
Summary
Ironwood must run a new Phase 3 trial after FDA talks, delaying its SBS drug approval despite strong results from prior studies.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 14, 2025 by benzinga